Form 4: Lixte Biotechnology Director Equity Swap

Director Guy Primus exchanged 25,000 stock options for 25,000 immediately vesting restricted share units.

Summary

• Director Guy Primus entered into a Stock Option Cancellation Agreement on April 15, 2026.
• The agreement involved the cancellation of 25,000 stock options originally granted on December 24, 2025, with an exercise price of $4.05.
• In exchange, the director received 25,000 restricted share units (RSUs) which vest immediately upon grant.
• The transaction results in the director holding 25,000 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event regarding director compensation that does not signal a change in the company's fundamental financial health.

Positives

• The conversion of options to RSUs simplifies the director's equity compensation structure.
• Immediate vesting of the 25,000 RSUs provides the director with full ownership of the underlying common stock.

Negatives

• The cancellation of options removes the potential for future leverage associated with option-based compensation.

Risks

• Equity-based compensation is subject to market volatility and the future performance of Lixte Biotechnology stock.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the change in the director's equity holdings.

Management Comments

• The RSUs were granted pursuant to the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan.

Industry Context

StockSavvy.ai notes that equity swaps of this nature are common in the biotechnology sector to align director incentives with immediate share ownership rather than long-term option exercise, often occurring during periods of corporate restructuring or compensation policy updates.

Comparison to Industry Standards

• The transition from options to RSUs is a standard practice in small-cap biotech firms to reduce dilution overhang and provide more predictable compensation for board members.
• Immediate vesting of director equity is consistent with standard retention practices for non-executive directors in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Shareholders may view the shift to RSUs as a standard adjustment to director compensation packages.

Next Steps

• No further actions or milestones were disclosed in this filing.

Key Dates

Keywords

LIXT, Lixte Biotechnology, Form 4, Insider Trading, Equity Compensation, Restricted Share Units, Director Compensation